---
authors:
- Kulkarni, Nita Shrikant
category: Clinical Review
clinical_significance: High
external_resources:
- title: PubMed Entry
  type: reference
  url: https://pubmed.ncbi.nlm.nih.gov/36791434/
file_path: 2023/02/enoxaparin-is-better-than-aspirin-for-the-prevention-of-veno.md
issue: '2'
keywords:
- Anticoagulants
- Postoperative Complications
- Humans
- Arthroplasty, Replacement, Knee
- Venous Thromboembolism
- Enoxaparin
- Aspirin
last_updated: '2025-07-30'
mesh_terms:
- Humans
- Enoxaparin
- Aspirin
- Venous Thromboembolism
- Arthroplasty, Replacement, Knee
- Anticoagulants
- Postoperative Complications
original_format: PubMed
pages: 200-201
patient_population: Adults
peer_reviewed: true
pmid: '36791434'
processed_date: '2025-07-30'
publication_date: '2023-02-01'
pubmed_enriched: true
pubmed_enriched_date: '2025-07-30'
reading_time_minutes: 5
source: American family physician
specialty:
- Family Medicine
status: processed
tags:
- clinical-review
- family-practice
- clinical-medicine
- pubmed-enhanced
title: Enoxaparin Is Better Than Aspirin for the Prevention of Venous Thromboembolism After Total Hip or Knee Arthroplasty.
topics:
- Family Medicine
volume: '107'
---

# Enoxaparin Is Better Than Aspirin for the Prevention of Venous Thromboembolism After Total Hip or Knee Arthroplasty.

**Authors:** Kulkarni, Nita Shrikant

**Published in:** American family physician | Vol. 107, No. 2 | 2023-02-01

**Links:** [PubMed](https://pubmed.ncbi.nlm.nih.gov/36791434/)

## Clinical Information

**Population:** Adults | **Clinical Significance:** High

## Topics & Specialties

**Specialties:** Family Medicine

**Topics:** Family Medicine

## MeSH Terms

Humans, Enoxaparin, Aspirin, Venous Thromboembolism, Arthroplasty, Replacement, Knee, Anticoagulants, Postoperative Complications

## Article Content

*Full article content to be extracted and formatted from source material.*

## Additional Resources

- [PubMed Entry](https://pubmed.ncbi.nlm.nih.gov/36791434/) (reference)

---

*Processed: 2025-07-30* | *PubMed Enhanced: 2025-07-30*
